This post from the Pharmalot blog indicates that all the perceived negatives that Dendreon's Provenge might be facing do NOT seem to be effecting the drug's initial acceptance. In a quick survey of 25% of the sites expected to prescribe Provenge - more than half plan to prescribe next month.
Provenge Launch Appears On Track: Analyst // Pharmalot.
Further, any doubts about reimbursement aren't effecting the prescribing physcians' intention to prescribe to additional patients. In fact, 8 of the 13 centers have a wait list. A high penetration rate is therefore expected in defiance of naysayers predictions.
Posted by Bruce Lehr July 26th 2010.
Luke Timmerman's comments on NEJM article
http://www.xconomy.com/seattle/2010/07/28/dendreon-gets-published-in-nejm/
Posted by: bigredbruce | 07/28/2010 at 05:49 PM
Ed Silverman's comments on Dendreon's appearance in NEJM
http://www.pharmalot.com/2010/07/dendreon-finally-gets-some-respect-sort-of/
Posted by: bigredbruce | 07/28/2010 at 05:48 PM
More on Dendreon's Provenge from Matt Herper's The Science blog.
http://blogs.forbes.com/sciencebiz/2010/07/dendreon-gets-some-respect/
Posted by: bigredbruce | 07/28/2010 at 04:18 PM